logo

For the Inventor, By the Inventor

Berlin, Germany

Bayer Schering Pharma Ag


USPTO Granted Patents = 192

% Expired Patents = 68.8



Trademarks = 16

Forward Citations = 1,427

Loading Chart...
Loading Chart...

492 inventors (with patents filed for the assignee):

goldMedal Sabine Leifeld (24 out of 28 patents)

silverMedal Heike Ranze (23 out of 24 patents)

bronzeMedal Parviz Bazargani (23 out of 23 patents)

4.  Karl-Heinz Schlemmer (12 out of 120 patents)

5.  Michael Wiklund (12 out of 20 patents)

6.  Markus Berger (10 out of 40 patents)

7.  Hartmut Rehwinkel (10 out of 53 patents)

8.  Werner Skuballa (10 out of 106 patents)

9.  Dieter Lang (9 out of 67 patents)

10.  Karl-Heinz Thierauch (9 out of 29 patents)

11.  Ilkka Jutila (8 out of 26 patents)

12.  Wolfgang Schwede (8 out of 41 patents)

13.  Stuart Ince (8 out of 15 patents)

14.  Olaf Prien (8 out of 14 patents)

15.  Elisabeth Perzborn (8 out of 101 patents)


Core Competencies:
Tumor Vasculature
Contraception
Quinolone Antibiotics
Antibody Molecules
Vascular Endothelial Growth Factor
Protein Kinase Inhibitors
Hormone Replacement Therapy
Transdermal Administration
Sustained-Release
Immunoconjugates
Antiphlogistics
Antiviral Agents

192 patents:

1. 8680117 - [object Object] (2014-03-25),
2. 8491906 - Selective targeting of tumor vasculature using antibody molecules (2013-07-23),
3. RE44159 - Composition for contraception (2013-04-15),
4. RE43916 - Composition for contraception (2013-01-07),
5. 8263040 - Metal chelates having a perfluorinated PEG radical, processes for their preparation, and their use (2012-09-11),
6. D665163 - Display screen for a pill dispenser (2012-08-14),
7. D665162 - Display screen for a pill dispenser (2012-08-14),
8. D665161 - Display screen for a pill dispenser (2012-08-14),
9. 8227598 - Heteroaryl carboxamides (2012-07-24),
10. 8211930 - Phenyl and benzodioxinyl substituted indazoles derivatives (2012-07-03),
11. 8188270 - Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide (2012-05-29),
12. 8187632 - Sustained-release preparations of quinolone antibiotics (2012-05-29),
13. D657550 - Portion of a display screen for a pill dispenser (2012-04-17),
14. D657549 - Portion of a display screen for a pill dispenser (2012-04-17),
15. D657548 - Portion of a display screen for a pill dispenser (2012-04-17),
Company Overview
Bayer Schering Pharma AG, headquartered in Berlin, specializes in the development and manufacturing of innovative pharmaceutical compositions. The company focuses on critical areas such as tumor vasculature, contraception, and quinolone antibiotics, contributing to advancements in healthcare. Its research encompasses antibody molecules, vascular endothelial growth factor, and protein kinase inhibitors, alongside hormone replacement therapy and transdermal administration technologies. Bayer Schering Pharma AG is committed to enhancing patient outcomes through its diverse therapeutic portfolio.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Bayer Schering Pharma Ag USPTO Patent Assignee Logo
192 Patents

#9 in D-1000 Berlin

#313 in Germany

#4,385 in the World

Berlin, DE
Berlin, Germany

Bayer Schering Pharma Ag

Forward Citations = 1,427

492 inventors:

goldMedal Sabine Leifeld (24 out of 28 patents)

silverMedal Heike Ranze (23 out of 24 patents)

bronzeMedal Parviz Bazargani (23 out of 23 patents)

4.  Karl-Heinz Schlemmer (12 out of 120 patents)

5.  Michael Wiklund (12 out of 20 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Bayer Schering Pharma Ag. Retrieved from https://idiyas.com/company/bayer-schering-pharma-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…